Merck (MRK) Cash & Current Investments (2009 - 2026)

Merck (MRK) has 18 years of Cash & Current Investments data on file, last reported at $5.7 billion in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $5.7 billion, down 38.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 billion (down 38.21% YoY), and the FY2025 annual result was $14.6 billion, up 6.4% from the prior year.
• Cash & Current Investments retreated to $5.7 billion in Q1 2026 per MRK's latest filing, from $14.6 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $18.2 billion in Q3 2025 and troughed at $5.6 billion in Q1 2024.
• A 5-year average of $10.5 billion and a median of $10.1 billion in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments sank 46.23% in 2023, then jumped 92.99% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $13.2 billion in 2022, then slumped by 46.23% to $7.1 billion in 2023, then soared by 92.99% to $13.7 billion in 2024, then climbed by 6.4% to $14.6 billion in 2025, then slumped by 60.85% to $5.7 billion in 2026.
• Business Quant data shows MRK's Cash & Current Investments at $5.7 billion in Q1 2026, $14.6 billion in Q4 2025, and $18.2 billion in Q3 2025.